Evoke® is the only spinal cord stimulation technology capable of measuring and recording each patient’s unique response to stimulation and makes automatic, real-time adjustments that deliver superior long-term pain relief.
Nearly 9 out of 10 Evoke Closed-Loop patients experience long-term pain relief
89.1%
at 12 months
EVOKE Study (U.S.)1
89.5%
at 24 months
AVALON Study (Australia)2
Reduce opioid intake
More than half of
Evoke Closed-Loop patients reduced
or eliminated opioids3
Evoke Closed-Loop patients reduced
or eliminated opioids3
Gain more sleep
Evoke Closed-Loop patients
gained an additional hour
of sleep per day4
gained an additional hour
of sleep per day4
Get back to living
Nearly 8 out of 10
Evoke Closed-Loop patients had
meaningful improvements
in their ability to perform
daily activities3
Evoke Closed-Loop patients had
meaningful improvements
in their ability to perform
daily activities3
Saluda News
Saluda listed in top 30 healthcare status ups in Australia
Exclusive list of top healthcare start ups in Australia.
Press Releases
Saluda Medical Expands Executive Leadership Team with Vision for Growth
Kristin Caplice to join as Chief Legal Officer Tim Benner as Chief Commercial Officer Artarmon, Australia...
References:
1. Deer T, Hagedorn J, Jameson J, Mekhail N. A new horizon in neuromodulation. Pain Medicine. 2020 Jun 28. doi: https://doi.org/10.1093/pm/pnaa197. 2. Russo M, Brooker C, Sullivan R, Taylor N, Holford L, Boesel T, Gmel G, Shariati N, Poree L, Parker J. Avalon study: long-term impact of ECAP-controlled closed-loop SCS on pain, patient wellbeing and clinical practice. Presented at: North American Neuromodulation Society (NANS) 2020 Annual Meeting; Las Vegas, NV. 3. Mekhail N, Levy RM, Deer TR, et al. Long-term safety and efficacy of closed-loop spinal cord stimulation to treat chronic back and leg pain (Evoke): a double-blind, randomised, controlled trial. Lancet Neurol. 2020;19(2):123-134. 4. Data on file.